News

EyePoint Pharmaceuticals Doses First Patient in LUGANO Trial

EyePoint Pharmaceuticals Doses First Patient in LUGANO Trial

Overview of EyePoint Pharmaceuticals' Latest Milestone

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a dedicated biopharmaceutical company focused on innovative therapies for retinal diseases, has recently marked a significant milestone in its journey by dosing the first patient in the Phase 3 LUGANO clinical trial of DURAVYU™, an investigational therapy aimed at treating wet age-related macular degeneration (wet AMD). This announcement was made from their base in Watertown, Massachusetts, indicating progress in their commitment to improving patient outcomes in serious retinal conditions.

Understanding the Significance of the LUGANO Trial

The initiation of this clinical trial represents a pivotal moment not only for EyePoint but also for the community of patients suffering from wet AMD. As the first patient is dosed, it reflects EyePoint's leadership in developing sustained-release ocular drug delivery systems. Dr. Jay S. Duker, President and CEO of EyePoint, emphasized the importance of this trial, stating that their efforts are directed toward following a non-inferiority approval pathway that aligns with the FDA’s guidance. This structured approach is designed to fast-track the availability of DURAVYU for patients who urgently need enhanced treatment options.

The Role of DURAVYU in Treating Wet AMD

DURAVYU is envisioned as a revolutionary treatment providing sustained release of vorolanib, a selective tyrosine kinase inhibitor. This therapy aims to address the challenges faced by patients, as the current standard of care for wet AMD requires frequent injections, contributing to a high burden of treatment and frequent patient follow-ups. Offering an injection every six months can alleviate some of these challenges, allowing more patients to maintain their vision effectively without the constant need for additional therapies.

Envisioning a New Era in AMD Management

The global LUGANO trial includes more than 150 clinical trial sites prepared to rapidly enroll eligible participants. Dr. Ramiro Ribeiro, Chief Medical Officer, expressed optimism regarding the exceptional enthusiasm from both patients and investigators toward the Phase 3 protocol. With both treatment-naïve and treatment-experienced patients included, the trials aim to reflect a more comprehensive view of the actual patient population affected by wet AMD.

Challenges Associated with Wet AMD Treatment

As discussed by Dr. Carl Regillo from Wills Eye Hospital, patients with wet AMD experience a significant unmet need for effective and safe treatment alternatives. Current methods, which typically involve bi-monthly injections, impose a heavy burden on patients which can lead to missed appointments and unaddressed disease progression. DURAVYU's potential to maintain patient health with fewer injections may significantly enhance patient adherence and overall outcomes.

Insights from Clinical Trials

Initial data from earlier clinical trials, including the DAVIO and DAVIO 2 trials, have shown strong efficacy and safety for DURAVYU in treating wet AMD. The results indicate a substantial reduction in the treatment burden, further supporting the movement towards a more patient-friendly therapeutic regimen that can be sustained over longer periods.

Looking Ahead: The Future of EyePoint Pharmaceuticals

With the LUGANO trial underway, EyePoint Pharmaceuticals is also preparing to initiate the LUCIA trial, further building on their robust research foundation. The outcomes from these trials are keenly anticipated in the coming years, with expectations set for data release in 2026. There’s also excitement surrounding the Phase 2 VERONA trial focusing on diabetic macular edema (DME), promising a comprehensive approach to retinal disease management.

The Technology Behind DURAVYU

Utilizing EyePoint's proprietary Durasert E™ technology, DURAVYU allows for a sustained release of medication directly into the eye, ensuring that patients receive the therapy they need without the logistical complications associated with frequent visits. This process makes it easier for patients, as it simplifies their treatment journey and potentially improves their quality of life.

Frequently Asked Questions

What is the purpose of the LUGANO trial?

The LUGANO trial aims to evaluate the efficacy and safety of DURAVYU in treating wet age-related macular degeneration.

How does DURAVYU differ from current treatments?

DURAVYU is designed for sustained release, offering patients potentially six months or longer between injections, compared to the standard treatments that require bi-monthly injections.

What are the expected outcomes from the LUGANO trial?

EyePoint anticipates that the trial will provide data supporting the safety and efficacy of DURAVYU, potentially changing the treatment landscape for wet AMD.

What other trials are ongoing at EyePoint Pharmaceuticals?

Aside from the LUGANO trial, EyePoint is also working on the LUCIA trial and the Phase 2 VERONA trial for diabetic macular edema.

Is DURAVYU approved for use?

Currently, DURAVYU is investigational and has not yet been approved by the FDA.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 488

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 299

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 248

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 348

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 371

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 347

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Hippo's Q3 2024 Results Showcase Growth and Financial Strength

Updated Category News Views 343

Hippo's Remarkable Financial Performance in Q3 2024 Hippo (NYSE: HIPO), a leader in home insurance dedicated to proactive protection, has unveiled its financial highlights for the third quarter of 2024. This announcement celebrates a continuation of their success, driven by strategic initiatives aimed at achieving profitable growth. Strong Revenue Growth Hippo reported...

Continue Reading
Alloy Personal Training's New Partnership Sets Growth Strategy

Updated Category News Views 225

Alloy Personal Training Partners with CapitalSpring for Expansion Alloy Personal Training recently announced an innovative collaboration with a reputable investment firm to boost its franchise growth and reach across the nation. This strategic partnership marks a notable chapter in the company’s history, reinforcing its commitment to a people-centric business model...

Continue Reading
Intel's Strategic Path Forward: Long-Term Growth in Focus

Updated Category News Views 918

Intel's Long-Term Commitment to Foundry Services Intel Corp (NASDAQ: INTC) has recently shared its strategic vision with employees, highlighting a gradual approach to growth instead of seeking quick profits. Analysts report that while there may not be any revolutionary announcements on the horizon, Intel's plans and intentions are coming into clearer focus. Analyst Harlan...

Continue Reading
Game-Changing PR: Good At Marketing's Exclusive Software

Updated Category News Views 41

Earned Media: The Overlooked Goldmine South Florida's advertising scene is a bit like a crowded beach with everyone scrambling for the same spot of sand. But Good At Marketing, based in Boynton Beach, is wading in deeper waters. They've cracked the code to something their competition hasn't even considered: earned media. Not your basic ad buy, this agency says earned...

Continue Reading
Zevra Therapeutics Reveals Impressive 2024 Financial Results

Updated Category News Views 236

Zevra Therapeutics Reports Strong Financial Results for 2024 In a significant step forward, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) has released its financial results for the full year of 2024, reporting impressive net revenues of $23.6 million. This figure includes remarkable fourth-quarter contributions, with net revenue reaching $12.0 million. Company's Strategic Moves...

Continue Reading